Research Article

High Expression of the Long Noncoding RNA SNHG15 in Cancer Tissue Samples Predicts an Unfavorable Prognosis of Cancer Patients: A Meta-Analysis

Cheng Zhang,1,2 Yang Ke,1 Xin Liu,3 Xinghong Wang,4 Yuehua Li,1 Jian Zhou,1 Heng Zhang,1 and Lin Wang1

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
2Department of Hepatobiliary Surgery, The Sixth People’s Hospital of Chengdu, Chengdu 610041, China
3Department of Dermatology, The Second Affiliated Hospital of Chengdu Medical College, Chengdu 610051, China
4Department of Hepatobiliary Surgery, The First People’s Hospital of Yunnan Province, Kunming 650032, China

Correspondence should be addressed to Lin Wang; wanglinfey@126.com

Received 23 December 2019; Revised 23 May 2020; Accepted 8 June 2020; Published 15 July 2020

Academic Editor: Reza Izadpanah

Copyright © 2020 Cheng Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although the prognostic value of lncRNA small nucleolar RNA host gene 15 (SNHG15) expression in cancers has been evaluated in many studies, the results remain controversial. This meta-analysis aimed to clarify the role of SNHG15 in the prognosis of different cancer patients. Materials and Methods. Eligible studies were selected from PubMed, PMC, EMBASE, Web of Science, and Cochrane Library according to the inclusion and exclusion criteria (up to December 20, 2019). The primary outcome was overall survival (OS) and recurrence-free survival (RFS). The secondary outcome was other clinicopathological parameters (including advanced TNM stage, lymph node metastasis, distant metastases, and gender). The Cancer Genome Atlas (TCGA) dataset was used to verify the analysis results. Results. Eleven eligible studies were eventually included, involving 9 different types of cancer and 1,079 patients. The high expression of SNHG15 was indicative of a significantly poor OS of cancer patients (HR = 1.96, 95% CI = 1.55–2.47, P < 0.00001). Subgroup analysis showed that the high expression of SNHG15 was associated with a significantly poor OS of patients with digestive cancer (HR = 1.91, 95% CI = 1.38–2.66, P = 0.0001), but not lung cancer (HR = 1.83, 95% CI = 0.89–3.76, P = 0.010). The RFS of patients with high expression of SNHG15 was shorter than that of patients with low expression of SNHG15 (HR = 2.03, 95% CI = 1.46–2.83, P < 0.00001). In addition, high SNHG15 expression level was significantly correlated with later TNM stage (OR = 3.05, 95% CI = 2.31–4.02, P < 0.00001), lymphatic metastasis (OR = 3.20, 95% CI = 2.30–4.45, P < 0.00001), and distant metastasis (OR = 5.05, 95% CI = 2.15–11.85, P = 0.0002). The TCGA verification results were consistent with those observed in our meta-analysis. Conclusion. High expression of the long noncoding RNA SNHG15 in cancer tissue samples predicts an unfavorable prognosis for cancer patients. LncRNA SNHG15 can be used as an adverse prognostic biomarker for cancer patients.

1. Introduction

Malignant tumors are among the leading causes of morbidity and mortality for people of all ages worldwide [1, 2]. Despite the considerable progress in cancer treatments such as immunotherapy and targeted therapy, the survival rate for most cancers is still low [3, 4]. Finding potential biomarkers of cancer prognosis and elucidating their role and mechanisms will greatly impact the care of cancer patients.

Long noncoding RNAs (lncRNAs) are transcripts with a length of more than 200 nucleotides and are widely found in nucleus, cytoplasm, and exosome [5]. They usually cannot be translated into specific proteins because they do not have functional open reading frames [6]. Over the past decade, many studies have reported the critical role of such transcripts in physiological processes, like embryogenesis, immune cell activation, blood cell maturation, and cell-to-cell communication [5, 7–9]. Moreover, many lncRNAs are
dysregulated in human cancers, and IncRNAs may act as oncogenes or tumor suppressors in tumorigenesis and metastasis processes [5, 10, 11]. They have been proven to be a novel and promising prognostic biomarker and treatment targets in human cancer [12, 13].

Small nucleolar RNA host gene 15 (SNHG15) is a newly discovered lncRNA located on chromosome 7p13 [14]. SNHG15 is reported to be significantly upregulated in a variety of cancer tissues compared with adjacent noncancer tissues [15–17], and abnormal overexpression of SNHG15 in cancer samples is associated with poor prognosis and high risk of metastasis in different cancers, including breast, colorectal, gastric, and prostate cancers [15, 18–28]. However, the prognostic value of SNHG15 expression in thyroid cancers and glioma is controversial [29, 30]. Therefore, we meta-analyzed all relevant publications and TCGA database to achieve a comprehensive understanding of the relationship between SNHG15 expression and cancer patient prognosis and evaluated whether SNHG15 could be a potential biomarker for the prognosis of cancer patients.

2. Materials and Methods

2.1. Literature Search Strategies. Article search was performed in the databases, including PubMed, PMC, EMBASE, Web of Science, and Cochrane Library. The time limit for searching was from the construction of these databases to December 20, 2019. The terms used for the search were as follows: (small nucleolar RNA host gene 15 OR SNHG15) AND (cancer OR carcinoma OR tumor OR neoplasm OR malignant). References of the literature included were also traced back.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria for research studies were as follows: (1) research conducted on any type of human cancer; (2) measuring the expression of SNHG15 in tumor tissue; (3) investigating the relationship between SNHG15 expression level and prognosis or clinicopathological characteristics; and (4) reporting the hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI), or with sufficient data available for calculation.

The exclusion criteria were as follows: (1) duplicate articles; (2) editorials, letters, expert opinions, case reports, and reviews.

The primary outcome was overall survival (OS) and recurrence-free survival (RFS). The secondary outcome was other clinicopathological characteristics (including TNM stage, lymph node metastasis, distant metastases, gender, and tumor size).

2.3. Data Collection. Two researchers independently (Cheng Zhang and Yang Ke) extracted data from each original publication, and a third researcher (Xin Liu) resolved the differences. The extracted information included name of the first author, year of publication, country, type of cancer, sample size, the detection method for lncRNA, internal control, outcome index, and cutoff value. For studies reporting only Kaplan–Meier curves, Engauge Digitizer (version 12.1) software was used to extract survival data [31] and the HRs and 95% CIs were calculated using the EXCEL program file provided by Tierney et al. [32]. The quality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS) criteria, including selection (4 points) and comparability (2 points); studies with NOS scores above 6 were considered of high quality.

2.4. Bioinformatics Analysis and Verification. Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/) was used to analyze the differential expression of SNHG15 between cancer and normal tissues and the correlation of SNHG15 expression with OS of different cancer types.

2.5. Statistical Analysis. Statistical analysis was performed using RevMan 5.3.3 software and Stata SE 15.1 software. HR for death or recurrence and 95% CI were calculated between the high and low SNHG15 expression group. Patients with HR ≥ 1 indicated a poor prognosis. Furthermore, the correlation between SNHG15 expression and clinicopathological characteristics was evaluated using OR and 95% CI. Heterogeneity between the included studies was determined by the $I^2$ value from the Cochrane Q test and the $P$ value from the chi-square test. If there was heterogeneity ($I^2 ≥ 50\%$ or $P < 0.05$), the results were summarized using a random-effects model. Instead, fixed-effects models were used for analysis. Otherwise, a random-effects model was applied. Begg’s funnel plot and Egger’s test were used to assess publication bias. A sensitivity analysis was applied to assess the stability of the results. $P ≤ 0.05$ was considered statistically significant.

3. Results

3.1. Characteristics of Included Studies. As shown in Figure 1, 59 articles were initially detected according to the search strategy, and 41 articles remained after removing duplicates. After carefully screening the titles and abstracts based on the inclusion and exclusion criteria, 26 articles were excluded, including reviews, conference abstracts, and unrelated studies. After reading the full text of the remaining 15 articles, 4 articles were excluded due to incomplete data. Finally, 11 studies involving 1,078 patients were included in the meta-analysis [15, 18, 19, 21–28].

All the 11 studies included were from China, with 9 different types of cancer, viz., hepatocellular carcinoma (HCC) [18], gastric cancer (GC) [19], colorectal cancer (CRC) [27], pancreatic cancer (PC) [21], non-small-cell lung cancer (NSCLC) [24–26], renal cell cancer (RCC) [22], thyroid cancer (TC) [23], breast cancer (BC) [25], and epithelial ovarian cancer (OC) [28]. All the included studies were tested for the expression of SNHG15 by quantitative reverse transcription PCR (qRT-PCR), but the cutoff value and the internal reference were different (Table 1). HR and 95% CI could be directly extracted in 2 studies [19, 23] and were calculated from the survival curve in the remaining 9 studies using the Engauge Digitizer software [31, 32]. The
characteristics of the included studies are summarized in Table 1.

3.2. Association between SNHG15 Expression and OS. The association between SNHG15 expression and OS was reported in the 11 studies [15, 18, 19, 21–28]. As there was no statistical heterogeneity among the 11 studies ($P = 0.99$, $I^2 = 0$%), a fixed-effects model was chosen to estimate the combined HR and 95% CI. The results showed that the HR for death between the high SNHG15 expression group and the low SNHG15 expression group was 1.96 (95% CI = 1.55–2.47, $P < 0.00001$; see Table 2 and Figure 2(a)).

Given that the 11 studies reported 9 different types of cancer, we divided these studies into three subgroups, including digestive system (including HCC, CRC, GC, and PC) [18, 19, 21, 27], respiratory system (including NSCLC) [24–26], and other systems (including RCC, TC, BC, and OC) [15, 22, 23, 28]. Since no significant heterogeneity between different subgroup studies was detected ($I^2 = 0$, $P = 0.74$ for digestive system, $I^2 = 0$, $P = 0.87$ for respiratory system, and $I^2 = 0$, $P = 0.92$ for other system), we used a fixed-effects model to complete the synthesis of the data. The results of the subgroup analysis showed that the HR and 95% CI for death between the high SNHG15 expression group and the low SNHG15 expression group in digestive, respiratory, and other cancers were 1.91 (95% CI = 1.38–2.66, $P = 0.0001$), 1.83 (95% CI = 0.89–3.76, $P = 0.10$), and 2.05 (95% CI = 1.41–2.97, $P = 0.0001$; see Table 2 and Figure 2(b)). Furthermore, we also performed a series of subgroup analyses based on cutoff values and internal controls. The results showed that when GAPDH or β-actin was used as an internal control, or median value was used as a cutoff test, high expression of SNHG15 was significantly associated with a shorter OS (see Table 2, Figures 3(a) and 3(b)).

3.3. Association between SNHG15 Expression and RFS. Three studies reported the association between SNHG15 expression and RFS [19, 25, 28]. As there was no statistical heterogeneity among the 3 studies ($I^2 = 0$, $P = 0.56$), a fixed-effects model was used. The combined HR for RFS between the high SNHG15 expression group and the low SNHG15 expression group was 2.03 (95% CI = 1.46–2.83, $P < 0.00001$; see Figure 4), suggesting that an increase in SNHG15 expression was significantly associated with a shorter OS.

3.4. Association between SNHG15 Expression and Other Clinicopathological Parameters. As shown in Table 3, high SNHG15 expression was associated with advanced TNM stage (OR = 3.05, 95% CI = 2.31–4.02, $P < 0.00001$; see Table 3 and Figure 5(a)), lymph node metastasis (OR = 3.20, 95% CI = 2.30–4.45, $P < 0.00001$; see Table 3 and Figure 5(b)), and distant metastases (OR = 5.05, 95% CI = 2.15–11.85, $P = 0.0002$; see Table 3 and Figure 5(c)). In contrast, no statistical correlation was observed between
| Study               | Year | Country | Cancer type | Detection method | Internal control | Cutoff  | Total sample | Expression | Tumor stage | Metastasis analysis | Outcome | HR estimation | NOS score |
|---------------------|------|---------|-------------|------------------|------------------|---------|--------------|------------|-------------|----------------------|----------|---------------|-----------|
| Zhang et al. [18]   | 2016 | China   | HCC         | qRT-PCR          | GAPDH            | Median  | 152          | High 77    | I–IV        | N/A                  | OS       | SC            | 8         |
| Chen et al. [19]    | 2016 | China   | GC          | qRT-PCR          | GAPDH            | Median  | 106          | Low 75     | I–IV        | DM/LNM               | OS/RFS   | Reported       | 7         |
| Gou et al. [21]     | 2018 | China   | PC          | qRT-PCR          | GAPDH            | Median  | 171          | 82         | I–IV        | LNM                  | OS       | SC            | 7         |
| Du et al. [22]      | 2018 | China   | RCC         | qRT-PCR          | β-Actin          | Median  | 96           | 47         | I–IV        | N/A                  | OS       | SC            | 7         |
| Wu et al. [23]      | 2018 | China   | TC          | qRT-PCR          | GAPDH            | Median  | 92           | 50         | I–IV        | LNM                  | OS       | Reported       | 9         |
| Cui et al. [24]     | 2018 | China   | NSCLC       | qRT-PCR          | GAPDH            | FC      | 55           | 28         | I–IV        | LNM                  | OS       | SC            | 7         |
| Dong et al. [25]    | 2018 | China   | NSCLC       | qRT-PCR          | GAPDH            | Median  | 49           | 23         | I–IV        | LNM                  | OS/RFS   | SC            | 7         |
| Jin et al. [26]     | 2018 | China   | NSCLC       | qRT-PCR          | GAPDH            | FC      | 35           | 20         | I–III       | LNM                  | OS       | SC            | 8         |
| Kong and Qiu [15]   | 2018 | China   | BC          | qRT-PCR          | GAPDH            | Median  | 58           | 29         | I–IV        | LNM                  | OS       | SC            | 7         |
| Huang et al. [27]   | 2019 | China   | CRC         | qRT-PCR          | GAPDH            | Median  | 91           | 46         | I–IV        | DM/LNM               | OS       | SC            | 8         |
| Qu et al. [28]      | 2019 | China   | OC          | qRT-PCR          | GAPDH            | Median  | 182          | 73         | I–IV        | N/A                  | OS/RFS   | SC            | 8         |

HCC: hepatocellular carcinoma; GC: gastric cancer; PC: pancreatic ductal cancer; RCC: renal cell carcinoma; TC: thyroid carcinoma; NSCLC, non-small-cell lung cancer; BC: breast cancer; CRC: colorectal cancer; EOC: epithelial ovarian cancer; qRT-PCR: quantitative reverse transcription PCR; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; FC: fold change; LNM: lymph node metastasis; DM: distant metastasis; N/A: not available; OS: overall survival; SC: survival curve; RFS: recurrence-free survival; HR: hazard ratio; and NOS: Newcastle-Ottawa Scale.
| Categories               | Study number [references] | Total sample | P value    | HR (95% CI) for OS | Heterogeneity | P (%) | P<sub>h</sub> | Model |
|-------------------------|---------------------------|--------------|------------|--------------------|---------------|-------|-------------|-------|
| OS                      | 11 [15, 18, 19, 21–28]    | 1087         | <0.00001   | 1.96 (1.55–2.47)   | 0             | 0.99  | Fixed       |
| Cancer type             |                           |              |            |                    |               |       |             |       |
| Digestive system        | 4 [18, 19, 21, 27]        | 520          | 0.0001     | 1.91 (1.38–2.66)   | 0             | 0.74  | Fixed       |
| Respiratory system      | 3 [24–26]                | 139          | 0.1        | 1.83 (0.89–3.76)   | 0             | 0.87  | Fixed       |
| Other systems           | 4 [15, 22, 23, 28]        | 428          | 0.0001     | 2.05 (1.41–2.97)   | 0             | 0.92  | Fixed       |
| Internal control        |                           |              |            |                    |               |       |             |       |
| GAPDH                   | 10 [15, 18, 19, 21, 23–28]| 991          | <0.00001   | 1.92 (1.51–2.45)   | 0             | 0.99  | Fixed       |
| β-Actin                 | 1 [22]                   | 96           | 0.0479     | 2.48 (1.01–6.12)   | N/A           | N/A   | N/A         |
| Cutoff                  |                           |              |            |                    |               |       |             |       |
| Median                  | 9 [15, 18, 19, 21–23, 25, 27, 28]| 997         | <0.00001   | 1.98 (1.55–2.52)   | 0             | 0.98  | Fixed       |
| Fold change             | 2 [24, 26]               | 90           | 0.21       | 1.72 (0.73–4.04)   | 0             | 0.65  | Fixed       |

OS: overall survival; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HR: hazard ratio; and N/A: not applicable.
SNHG15 expression and gender ($P = 0.30$; see Table 3 and Figure 5(d)) and tumor size ($P = 0.77$; see Table 3 and Figure 5(e)). Additionally, due to insufficient age-related data on tumor differentiation in the included studies, no meta-analysis was performed on the association between SNHG15 expression and these clinical-pathological parameters.

### 3.5. Sensitivity Analysis and Publication Bias

As shown in Figure 6(a), the deletion of any included studies had no significant impact on the results, suggesting that our results were reasonable and reliable.

Furthermore, we performed Begg’s funnel plot and Egger’s test to evaluate the publication bias of the correlation between SNHG15 expression and OS. The Begg funnel plot is shown in Figure 6(b), and the results of the Egger test was $P = 0.409$. The results indicated no significant publication bias in the studies included in this meta-analysis.

The sensitivity analysis and Begg’s test between SNHG15 expression and RFS were also performed, and the results
| Study or subgroup | Log (hazard ratio) | SE  | Weight (%) | Hazard ratio IV, fixed, 95% CI | Hazard ratio IV, fixed, 95% CI |
|------------------|-------------------|-----|------------|-------------------------------|-------------------------------|
| GAPDH            |                   |     |            |                               |                               |
| Chen et al. (2016) | 1.07              | 0.41| 9.0        | 2.92 (1.31, 6.51)             |                               |
| Cui et al. (2018) | 0.8               | 0.71| 3.0        | 2.23 (0.55, 8.95)             |                               |
| Dong et al. (2018)| 0.76              | 0.68| 3.3        | 2.14 (0.56, 8.11)             |                               |
| Gou et al. (2018) | 0.57              | 0.26| 22.3       | 1.77 (1.06, 2.94)             |                               |
| Huang et al. (2019)| 0.52          | 0.58| 4.5        | 1.68 (0.54, 5.24)             |                               |
| Jin et al. (2018) | 0.39              | 0.55| 5.0        | 1.48 (0.50, 4.34)             |                               |
| Kong and Qiu (2018)| 0.59             | 0.52| 5.6        | 1.80 (0.65, 5.00)             |                               |
| Qu et al. (2019)  | 0.63              | 0.26| 22.3       | 1.88 (1.13, 3.13)             |                               |
| Wu et al. (2018)  | 0.9               | 0.46| 7.1        | 2.46 (1.00, 6.06)             |                               |
| Zhang et al. (2016)| 0.57             | 0.29| 17.9       | 1.77 (1.00, 3.12)             |                               |
| Subtotal (95% CI) |                   |     |            | 100.00                       | 1.92 (1.51, 2.45)             |

Heterogeneity: $\chi^2 = 1.88$, $df = 9$ ($P = 0.99$); $I^2 = 0$
Test for overall effect: $Z = 5.53$ ($P < 0.00001$)

| β-Actin |                   |     |            |                               |                               |
|---------|-------------------|-----|------------|-------------------------------|-------------------------------|
| Du et al. (2018) | 0.91              | 0.46| 100.0      | 2.48 (1.01, 6.12)             |                               |
| Subtotal (95% CI) |                   |     |            | 100.00                       | 2.48 (1.01, 6.12)             |

Heterogeneity: not applicable
Test for overall effect: $Z = 1.98$ ($P = 0.05$)

(b)

**Figure 3:** Forest plot for the association between SNHG15 expression and OS in a subgroup analysis based on (a) internal control and (b) cutoff.

**Figure 4:** Forest plot for association between SNHG15 expression and RFS.
| Clinicopathological parameters                           | Study number [references] | Total sample | \( P \) value | OR (95% CI) for OS | Heterogeneity | \( \sqrt{V} \) (%) | \( P_h \) | Model |
|---------------------------------------------------------|---------------------------|--------------|----------------|-------------------|---------------|---------------------|---------|-------|
| Gender (male vs. female)                                 | 9 [18, 19, 21–27]         | 847          | 0.30           | 0.87 (0.66–1.14)  | 30            | 0.18                | Fixed   |       |
| Tumor size (>5 cm vs. ≤5 cm)                            | 3 [18, 19, 25]            | 317          | 0.77           | 1.17 (0.41–3.36)  | 78            | 0.01                | Random  |       |
| TNM stage (III-IV vs. I-II)                             | 9 [15, 18, 19, 22–25, 27] | 999          | <0.00001       | 3.05 (2.31–4.02)  | 0             | 0.82                | Fixed   |       |
| Lymph node metastasis (yes vs. no)                      | 8 [15, 19, 21, 23–27]     | 657          | <0.00001       | 3.20 (2.30–4.45)  | 0             | 0.87                | Fixed   |       |
| Distant migration (yes vs. no)                          | 2 [19, 27]                | 197          | 0.0002         | 5.05 (2.15–11.85) | 0             | 0.43                | Fixed   |       |

OR: odds ratio; OS: overall survival; and CI: confidence interval.
Figure 5: Continued.
**Figure 5:** Forest plots for the association between SNHG15 expression and (a) TNM stage (III-IV vs. I-II), (b) lymph node metastasis (yes vs. no), (c) distant metastasis (yes vs. no), (d) gender (male vs. female), and (e) tumor size (>5 cm vs. ≤5 cm).

**Figure 6:** Sensitivity analysis and publication bias. (a) Sensitivity analysis of the association between SNHG15 expression and OS. (b) Begg’s funnel plot of publication bias for OS.
suggested that our results on RFS were reasonable and reliable (see Figures S1(a) and S1(b)).

3.6. Verification Results in the TCGA Dataset. We evaluated the correlation between SNHG15 expression and OS in the 9 malignant tumors involved in this meta-analysis from the TCGA dataset. According to the median expression of SNHG15 in each of the 9 malignant tumors, patients with an expression level higher than the median were considered in the high-expression group, and patients with an expression level lower than the median were considered in the low-expression group. As shown in Figure 7(a), the cancer patient population with high SNHG15 expression levels had a significantly poorer OS than those with low SNHG15 expression levels (HR = 1.2, P = 0.012), which was consistent with our meta-analysis results. We also evaluated the correlation between SNHG15 expression and OS in digestive (including HCC, CRC, GC, and PC), respiratory (including lung adenocarcinoma (LUAD) and lung squamous cell cancer (LUSC), from the TCGA dataset.

![Survival curves of SNHG15 expression in the TCGA dataset.](image1)

![Survival curves of SNHG15 expression in the TCGA dataset.](image2)

![Survival curves of SNHG15 expression in the TCGA dataset.](image3)

![Survival curves of SNHG15 expression in the TCGA dataset.](image4)

Figure 7: Validation of SNHG15 in the TCGA dataset. (a) Survival curves of SNHG15 are plotted for 9 kinds of cancers involved in this meta-analysis from the TCGA dataset. (b) Survival curves of SNHG15 are plotted for digestive cancers, including hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC), and pancreatic cancer (PC), from the TCGA dataset. (c) Survival curves of SNHG15 are plotted for other cancers, including renal cell cancer (RCC), thyroid cancer (TC), breast cancer (BC), and epithelial ovarian cancer (OC), from the TCGA dataset. (d) Survival curves of SNHG15 are plotted for non-small-cell lung cancer, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), from the TCGA dataset.
SNHG15 is one of the newly discovered popular lncRNAs associated with poor prognosis of patients with different types of cancer [15, 18, 23, 25, 27, 28]. Furthermore, the high expression of GC, BC, CRC, HCC, NSCLC, TC, and OV is highly expressed in various malignant tumors, including then, a large number of studies have reported that SNHG15 with a short half-life in a cell stress response study [33]. Since malignant tumors. SNHG15 was first identified as an lncRNA involved in the development and progression of many cancers. Previous studies have found that SNHG15 expression contributes to cisplatin resistance in BC [37] and temozolomide resistance in glioma [38]. In the present study, we found that SNHG15 expression correlated with lymphatic metastasis, distant metastasis, and later TNM stages, suggesting that (1) increased expression of SNHG15 may be closely related to the advanced characteristics of cancer; (2) clarification of the relationships between SNHG15 expression and clinical parameters may allow the identification of the patient population who can potentially benefit from chemotherapy.

Some molecular mechanisms were revealed by which SNHG15 acts as an oncogene. In the nucleus, SNHG15 can interact with the zinc finger domain of Slug, inhibiting Slug ubiquitination, and then the redundant Slug proteins inhibit E-cadherin transcription, promote the epithelial–mesenchymal transition (EMT), and stimulate the invasion and metastasis of the colon, breast, and renal cancer cells [22, 34]. In pancreatic cancer, SNHG15 can also bind to the enhancer of zeste homolog 2 and inhibit the expression of p15 and the Kruppel-like factor 2 by zeste homolog 2-mediated H3 lysine 27 trimethylation modification and finally promote the proliferation of pancreatic cancer cells [20]. In the cytoplasm, SNHG15 can also act as the competing endogenous RNA and competitively bind to a variety of microRNAs, influence the expression of multiple invasion related proteins, and thereby promote the proliferation, invasion, and migration of malignant tumor cells [35]. For example, in osteosarcoma, SNHG15 can directly bind miR-141 as a “molecular sponge” to promote osteosarcoma expression and cancer growth [36].

Different cancers display distinct clinical characteristics and biological behaviors. To reduce the heterogeneity between studies, a subgroup study was performed based on pathological classification. The results suggested that the increase of SNHG15 expression in the digestive subgroup (including HCC, CRC, GC, and PC) and RCC, TC, BC, and OC subgroup was significantly associated with a shorter OS, which suggested that SNHG15 may be a reliable prognostic biomarker for cancers of the digestive, urinary, thyroid, and reproductive organs. However, there was no significant correlation detected between SNHG15 and NSCLC.

Chemotherapy is a main treatment approach for various cancers. Previous studies have found that SNHG15 expression contributes to cisplatin resistance in BC [37] and temozolomide resistance in glioma [38]. In the present study, we found that SNHG15 expression correlated with lymphatic metastasis, distant metastasis, and later TNM stages, suggesting that (1) increased expression of SNHG15 may be closely related to the advanced characteristics of cancer; (2) clarification of the relationships between SNHG15 expression and clinical parameters may allow the identification of the patient population who can potentially benefit from chemotherapy.
Our study included a large number of samples, which confers a high statistical power. Therefore, the results of the present study are more stable and accurate than those of previous individual studies. However, some limitations should be noted in this meta-analysis. First, all studies were from China, so we used the TCGA database, which includes cancer cases from multiple regions including African American, American native, and Caucasian, to verify our meta-analysis results. Indeed, the bioinformatics results support our meta-analysis. A large sample size with multiple races is needed to confirm our findings in the future. Second, given the fact that individual patient data were not analyzed, certain data on the relationships between clinical parameters and SNHG15 could not be combined.

5. Conclusions

In conclusion, this is the first meta-analysis reporting that LncRNA SNHG15 can be used as a prognostic biomarker for cancer patients, especially cancers in the digestive, urinary, thyroid, and reproductive systems. In addition, the high expression level of SNHG15 was closely related to the advanced characteristics of cancer, indicating that patients without these advanced characteristics may be prime candidates for chemotherapy. More high-quality and large-sample studies are required to further confirm the prognostic role of SNHG15 in cancer.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Cheng Zhang, Yang Ke, Xin Liu, and Xinghong Wang contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant nos. 81660399 and 81860423), the Innovative Research Team Project of Yunnan Province (Grant no. 2015HC033), the Yunnan Provincial Academician Workstation of Xiaoping Chen (Grant no. 2017(C)018), the Breeding Program for Major Scientific and Technological Achievements of Kunming Medical University (Grant no. CGYP201607), the Medical Leading Talent Project of Yunnan Province (Grant no. L201622), Yunnan Provincial Clinical Center of Hepato-Biliary-Pancreatic Diseases to L. W., the Applied Fundamental Research Joint Program of Science & Technology Department of Yunnan Province and Kunming Medical University (Youth Ph.D. Fund), the Leading Academic and Technical Young and Mid-Aged Program of Kunming Medical University (Grant no. 60118260108), and the Educational Reform and Educational Reform Program of Kunming Research and Education University (Grant no. 2019-JY-Z-12) to Y. K.

Supplementary Materials

Figure S1: sensitivity analysis and publication bias. (a) Sensitivity analysis of the association between SNHG15 expression and association and recurrence-free survival (RFS), (b) Begg’s funnel plot of publication bias for RFS. (Supplementary Materials)

References

[1] C. Fitzmaurice, C. Fitzmaurice, T. F. Akinyemiju et al., “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study,” *JAMA Oncology*, vol. 4, no. 11, pp. 1553–1568, 2018.
[2] I. Soerjomataram, J. Lortet-Tieulent, D. M. Parkin et al., “Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions,” *The Lancet*, vol. 380, no. 9586, pp. 1840–1850, 2012.
[3] V. Subbiah and R. Kurzrock, “Debunking the delusion that precision oncology is an illusion,” *The Oncologist*, vol. 22, no. 8, pp. 881–882, 2017.
[4] V. Prasad, “Perspective: the precision-oncology illusion,” *Nature*, vol. 537, no. 7619, p. S63, 2016.
[5] M. Dragomir, B. Chen, and G. A. Calin, “Exosomal LncRNAs as new players in cell-to-cell communication,” *Translational Cancer Research*, vol. 7, no. 2, pp. S243–S252, 2018.
[6] Y. Okazaki, M. Furuno, T. Kasukawa et al., “Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs,” *Nature*, vol. 420, no. 6915, pp. 563–573, 2002.
[7] I. E. Schor, G. Bussotti, M. Malek et al., “Non-coding RNA expression, function, and variation during drosophila embryogenesis,” *Current Biology*, vol. 28, no. 22, pp. 3547–3561.e9, 2018.
[8] H. Xu, Y. Jiang, X. Xu et al., “Inducible degradation of lncRNA srsr1 promotes IFN-γ-mediated activation of innate immune responses by stabilizing stat1 mRNA,” *Nature Immunology*, vol. 20, no. 12, pp. 1621–1630, 2019.
[9] J. R. Alvarez-Dominguez, W. Hu, B. Yuan et al., “Global discovery of erythroid long noncoding RNAs reveals novel regulators of red cell maturation,” *Blood*, vol. 123, no. 4, pp. 570–581, 2014.
[10] Y. Ye, J. Guo, P. Xiao et al., “Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma,” *Cancer Letters*, vol. 469, pp. 310–322, 2020.
[11] J. Kim, H.-L. Piao, B.-J. Kim et al., “Long noncoding RNA MALAT1 suppresses breast cancer metastasis,” *Nature Genetics*, vol. 50, no. 12, pp. 1705–1715, 2018.
[12] B. Pardini, A. A. Sabo, G. Birolo, and G. A. Calin, “Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies,” *Cancers*, vol. 11, no. 8, p. 1170, 2019.
[13] M. P. Dragomir, S. Kopetz, J. A. Ajani, and G. A. Calin, “Noncoding RNAs in GI cancers: from cancer hallmarks to clinical utility,” *Gut*, vol. 69, no. 4, pp. 748–763, 2020.
[14] K. T. Tycowski, C. M. Smith, M.-D. Shu, and J. A. Steitz, "A small nucleolar RNA requirement for site-specific ribose methylation of rRNA in Xenopus," Proceedings of the National Academy of Sciences, vol. 93, no. 25, pp. 14480–14485, 1996.

[15] Q. Kong and M. Qiu, "Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p," Biochemical and Biophysical Research Communications, vol. 495, no. 2, pp. 1594–1600, 2018.

[16] X. Sun, Y. Bai, C. Yang, S. Hu, Z. Hou, and G. Wang, "Long noncoding RNA SNHG15 enhances the development of colorectal carcinoma via functioning as a ceRNA through miR-141/SIRT1/Wnt/β-catenin axis," Artificial Cells, Nanomedicine, and Biotechnology, vol. 47, no. 1, pp. 2536–2544, 2019.

[17] Y. Zhang, D. Zhang, J. Lv, S. Wang, and Q. Zhang, "LncRNA SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBP1A axis," Gene, vol. 705, pp. 44–50, 2019.

[18] J.-H. Zhang, H.-W. Wei, and H.-G. Yang, "Long noncoding RNA SNHG15, a potential prognostic biomarker for hepatocellular carcinoma," European Review for Medical and Pharmacological Sciences, vol. 20, no. 9, pp. 1720–1724, 2016.

[19] S.-X. Chen, J.-F. Yin, B.-C. Lin et al., "Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC," Tumour Biology, vol. 37, no. 5, pp. 6801–6812, 2016.

[20] Z. Ma, H. Huang, J. Wang et al., "Long non-coding RNA SNHG15 inhibits P15 and KLF2 expression to promote pancreatic cancer proliferation through EZH2-mediated H3K27me3," Oncotarget, vol. 8, no. 48, pp. 84153–84167, 2017.

[21] X.-B. Guo, H.-S. Yin, and J.-Y. Wang, "Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma," European Review for Medical and Pharmacological Sciences, vol. 22, no. 18, pp. 5892–5898, 2018.

[22] Y. Du, C. Kong, Y. Zhu et al., "Knockdown of SNHG15 suppresses renal cell carcinoma proliferation and EMT by regulating the NF-κB signaling pathway," International Journal of Oncology, vol. 53, no. 1, pp. 384–394, 2018.

[23] D.-M. Wu, S. Wang, X. Wen et al., "LncRNA SNHG15 acts as a ceRNA to regulate YAP1-hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma," Cell Death & Disease, vol. 9, no. 10, p. 947, 2018.

[24] H.-X. Cui, M.-Y. Zhang, K. Liu, J. Liu, Z.-L. Zhang, and L. Fu, "LncRNA SNHG15 promotes proliferation and migration of lung cancer via targeting microRNA-211-3p," European Review for Medical and Pharmacological Sciences, vol. 22, no. 20, pp. 6838–6844, 2018.

[25] Y.-Z. Dong, X.-M. Meng, and G.-S. Li, "Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion," European Review for Medical and Pharmacological Sciences, vol. 22, no. 9, pp. 2671–2679, 2018.

[26] B. Jin, H. Jin, H.-B. Wu, J.-J. Xu, and B. Li, "Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis," Journal of Cellular Physiology, vol. 233, no. 9, pp. 7164–7172, 2018.

[27] L. Huang, H. Lin, L. Kang et al., "Aberrant expression of long noncoding RNA SNHG15 correlates with liver metastasis and poor survival in colorectal cancer," Journal of Cellular Physiology, vol. 234, no. 5, pp. 7032–7039, 2019.